BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity.
- LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembrane protein with zinc transporter and metalloproteinase activity.
- BRY812 is a LIV-1 targeting ADC developed on BioRay's CysLink™ technology platform where highly stable conjugation is created through irreversible chemistry.
- Globally, no LIV-1 targeting ADC has received marketing approval yet, and BioRay's BRY812 is anticipated to be the second LIV-1 ADC that reaches the clinical stage.
- Dr. Haibin Wang, CEO of BioRay, stated, "Since this January, we have obtained the IND approval of two innovative antibody drug candidates, BR108 and BRY805.